This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Eli Lilly to buy Ventyx Biosciences for $1.2bn

( January 7, 2026, 22:35 GMT | Official Statement) -- MLex Summary: Eli Lilly and Company is proposing to acquire Ventyx Biosciences, Inc. in a deal worth approximately $1.2 billion, the companies announced Wednesday. Ventyx's pipeline of small molecule therapeutics that are designed to treat inflammation across a broad range of diseases was cited by Lilly as addressing a critical area of need for patients with chronic diseases. The companies expect the deal to close in the first half of 2026.Full release follows:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login